GeneBioHealth Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2013

Location

Shenzhen Guangdong China

Primary Industry

Medical Devices & Equipment

About

Based in Shenzhen, China and founded in 2013, GeneBioHealth operates as a diagnostic reagent developer that focuses on in vitro diagnostics (IVD) and healthcare. The company headquarter in Shenzhen has 1500 square meters. And has over 500 square meters of GMP standard workshop. Haoyang Yu is the founder of the company, once served as project manager of R&D and quality safety headquarters of Bayer Pharmaceutical Co., Ltd. In January 2017, GeneBioHealth passed the ISO13485 certification. In March 2018, GeneBioHealth's product - Ruichangtai ® MiR-92a test kit was approved for listing. Its products include tumor diagnosis, Covid-19 protection, immunodiagnosis (POCT) and instrument. Covid-19 protection includes SARS-CoV-2 IgM/IgG test kit(colloidal gold), SARS-COV-2 nucleic acid test kit (RT-PCR) and Baihuikang hypochlorous acid disinfectant. POCT includes the testing of cardiovascular, inflammatory and digestive function. The company's services include detection of tumor, membership service, detection report and health file.

Current Investors

BOC & Utrust Fund

Request a demo to show more

Primary Industry

Medical Devices & Equipment

Sub Industries

Diagnostic, Medical & Imaging Laboratories, Diagnostic Equipment

Website

www.genebiohealth.com

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.